JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
137.64 USD
+1.34 (+0.98%)
137.64 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to JAZZ. JAZZ was compared to 192 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. A decent growth rate in combination with a cheap valuation! Better keep an eye on JAZZ.
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
JAZZ had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
In the past 5 years JAZZ always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of -3.70%, JAZZ is doing good in the industry, outperforming 74.48% of the companies in the same industry.
With a decent Return On Equity value of -10.92%, JAZZ is doing good in the industry, outperforming 72.92% of the companies in the same industry.
JAZZ's Return On Invested Capital of 5.47% is amongst the best of the industry. JAZZ outperforms 83.33% of its industry peers.
The Average Return On Invested Capital over the past 3 years for JAZZ is significantly below the industry average of 15.40%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(5.47%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| ROIC | 5.47% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
In the last couple of years the Profit Margin of JAZZ has declined.
JAZZ has a better Operating Margin (15.03%) than 85.42% of its industry peers.
JAZZ's Operating Margin has declined in the last couple of years.
JAZZ has a Gross Margin of 88.71%. This is amongst the best in the industry. JAZZ outperforms 91.67% of its industry peers.
In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.03% | ||
| PM (TTM) | N/A | ||
| GM | 88.71% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
Compared to 1 year ago, JAZZ has less shares outstanding
Compared to 5 years ago, JAZZ has more shares outstanding
Compared to 1 year ago, JAZZ has a worse debt to assets ratio.
2.2 Solvency
JAZZ has an Altman-Z score of 1.42. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of JAZZ (1.42) is better than 60.42% of its industry peers.
JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
JAZZ has a Debt to FCF ratio of 4.33. This is amongst the best in the industry. JAZZ outperforms 84.90% of its industry peers.
A Debt/Equity ratio of 1.17 is on the high side and indicates that JAZZ has dependencies on debt financing.
JAZZ has a worse Debt to Equity ratio (1.17) than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.42 |
ROIC/WACC0.74
WACC7.36%
2.3 Liquidity
A Current Ratio of 1.62 indicates that JAZZ should not have too much problems paying its short term obligations.
The Current ratio of JAZZ (1.62) is worse than 66.15% of its industry peers.
A Quick Ratio of 1.37 indicates that JAZZ should not have too much problems paying its short term obligations.
JAZZ's Quick ratio of 1.37 is on the low side compared to the rest of the industry. JAZZ is outperformed by 64.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
The earnings per share for JAZZ have decreased strongly by -62.78% in the last year.
JAZZ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.47% yearly.
The Revenue has been growing slightly by 4.52% in the past year.
JAZZ shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.48% yearly.
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%
3.2 Future
Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 6.88% on average per year.
The Revenue is expected to grow by 6.33% on average over the next years.
EPS Next Y-74.4%
EPS Next 2Y3%
EPS Next 3Y5.51%
EPS Next 5Y6.88%
Revenue Next Year4.37%
Revenue Next 2Y5.22%
Revenue Next 3Y5.8%
Revenue Next 5Y6.33%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.73, JAZZ is valued on the expensive side.
Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 81.77% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.11, JAZZ is valued a bit cheaper.
A Price/Forward Earnings ratio of 6.12 indicates a rather cheap valuation of JAZZ.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaper than 94.79% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of JAZZ to the average of the S&P500 Index (22.55), we can say JAZZ is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.73 | ||
| Fwd PE | 6.12 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 89.58% of the companies listed in the same industry.
93.23% of the companies in the same industry are more expensive than JAZZ, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.73 | ||
| EV/EBITDA | 8.99 |
4.3 Compensation for Growth
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.79
EPS Next 2Y3%
EPS Next 3Y5.51%
5. Dividend
5.1 Amount
JAZZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
137.64
+1.34 (+0.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.51%
Inst Owner Change-0.64%
Ins Owners2.49%
Ins Owner Change0.32%
Market Cap8.35B
Revenue(TTM)4.09B
Net Income(TTM)-404841000
Analysts84.8
Price Target193.36 (40.48%)
Short Float %7.98%
Short Ratio6.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.5%
Min EPS beat(2)-64.64%
Max EPS beat(2)-6.35%
EPS beat(4)2
Avg EPS beat(4)-10.46%
Min EPS beat(4)-64.64%
Max EPS beat(4)17.85%
EPS beat(8)3
Avg EPS beat(8)-9.87%
EPS beat(12)4
Avg EPS beat(12)-16.71%
EPS beat(16)7
Avg EPS beat(16)-10.46%
Revenue beat(2)0
Avg Revenue beat(2)-6.37%
Min Revenue beat(2)-10.66%
Max Revenue beat(2)-2.09%
Revenue beat(4)1
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.73%
Revenue beat(12)1
Avg Revenue beat(12)-2.38%
Revenue beat(16)3
Avg Revenue beat(16)-2.09%
PT rev (1m)1.53%
PT rev (3m)1.85%
EPS NQ rev (1m)-2.65%
EPS NQ rev (3m)16.14%
EPS NY rev (1m)0.91%
EPS NY rev (3m)11.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.73 | ||
| Fwd PE | 6.12 | ||
| P/S | 2.04 | ||
| P/FCF | 6.73 | ||
| P/OCF | 6.34 | ||
| P/B | 2.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.99 |
EPS(TTM)6.64
EY4.82%
EPS(NY)22.48
Fwd EY16.33%
FCF(TTM)20.44
FCFY14.85%
OCF(TTM)21.69
OCFY15.76%
SpS67.37
BVpS61.1
TBVpS-47.92
PEG (NY)N/A
PEG (5Y)3.79
Graham Number95.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| ROCE | 6.92% | ||
| ROIC | 5.47% | ||
| ROICexc | 6.73% | ||
| ROICexgc | 82.21% | ||
| OM | 15.03% | ||
| PM (TTM) | N/A | ||
| GM | 88.71% | ||
| FCFM | 30.34% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.37 | ||
| Cap/Depr | 11.29% | ||
| Cap/Sales | 1.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.28% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 1.42 |
F-Score5
WACC7.36%
ROIC/WACC0.74
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
EPS Next Y-74.4%
EPS Next 2Y3%
EPS Next 3Y5.51%
EPS Next 5Y6.88%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%
Revenue Next Year4.37%
Revenue Next 2Y5.22%
Revenue Next 3Y5.8%
Revenue Next 5Y6.33%
EBIT growth 1Y-0.29%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-54.85%
EBIT Next 3Y4.81%
EBIT Next 5Y7.57%
FCF growth 1Y25.59%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y-4.47%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
What is the valuation status of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
How financially healthy is JAZZ PHARMACEUTICALS PLC?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
Can you provide the expected EPS growth for JAZZ stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -74.4% in the next year.